Postoperative adjuvant PD-1 immunotherapy survival and body-mass-index dynamics in esophageal cancer: A real-world retrospective study
Adjuvant immunotherapy for EC shows good efficacy and safety. A BMI difference < 3.86 is a protective factor for PFS, highlighting the importance of monitoring nutrition and inflammation for personalized treatment.
Authors
- Liu-Yu Li
- Weijing Jiang
- Wenmin Ying (ORCID: https://orcid.org/0000-0002-5532-8199)
- Tao Xiong (ORCID: https://orcid.org/0000-0002-9773-649X)
- Meiqing Zhang (ORCID: https://orcid.org/0000-0002-5006-1915)
- Zhichao Fu (ORCID: https://orcid.org/0000-0003-0341-106X)
- Wenzhen Zhang (ORCID: https://orcid.org/0000-0003-3368-857X)
- Fengmei Wang (ORCID: https://orcid.org/0000-0001-9287-4183)
Institutions
- Fujian Medical University (CN)
- Fuzhou Pulmonary Hospital of Fujian (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.4251/wjgo.v17.i8.108484
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00